Education
About Us
Working with TipRanks
Follow Us
BrightSpring Health Services, Inc. (BTSG)
NASDAQ:BTSG
RESEARCH TOOLSreports
BTSG Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BTSG Stock 12 Month Forecast
Average Price Target
$26.54
▲(12.94%Upside)
| Highest Price Target$30.00 | Average Price Target$26.54 | Lowest Price Target$22.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$26
Hold
10.64%
Upside
Downgraded
06/05/25
BTIG
$25→$30
Buy
27.66%
Upside
Reiterated
05/29/25
Bank of America Securities
$25→$26.75
Buy
13.83%
Upside
Reiterated
05/13/25
Wells Fargo
$25→$27
Buy
14.89%
Upside
Reiterated
05/12/25
Morgan Stanley
$20→$25
Buy
6.38%
Upside
Reiterated
05/09/25
Leerink Partners
$26.5→$28.5
Buy
21.28%
Upside
Reiterated
05/06/25
Mizuho Securities
$22
Buy
-6.38%
Downside
Reiterated
03/12/25
Jefferies
$25
Buy
6.38%
Upside
Reiterated
03/06/25
Analysts Are Bullish on These NA Stocks: BrightSpring Health Services, Inc. (BTSG), Serve Robotics Inc (SERV)We remain bullish on BTSG and highlight how the recent sell-off in the stock has brought its valuation down to a very compelling level at 10.5x '25 EBITDA. Growth across BTSG's businesses is robust, which puts consolidated EBITDA growth around mid-teens %, and mgmt continues to execute & deliver consistent beats and raises that together, merit multiple expansion/stock upside from current levels. DC concerns are unwarranted. 4Q Results & Consistent With Pre-Release, Guidance Raised Already. BTSG's 4Q print was in-line with their pre-release from Jan, with Revs coming in at $3.05B & EBITDA at $167MM. Despite only issuing their initial FY25 guide in Jan, mgmt inched both top-line ($100MM higher from Rx segment) and EBITDA ($5MM raise vs. prior $547.5MM mid-pt) higher.
UBS
$22→$30
Buy
27.66%
Upside
Reiterated
01/29/25
Unknown AnalystGoldman Sachs
Not Ranked
Goldman Sachs
$22
Buy
-6.38%
Downside
Reiterated
12/16/24
reiterate our Buy ratings on BTSG ($22 target price, 22% upside)
CJS Securities
$27
Buy
14.89%
Upside
Initiated
12/12/24
Deutsche Bank
$13→$20
Buy
-14.89%
Downside
Reiterated
11/04/24
Unknown AnalystKeyBanc
Not Ranked
KeyBanc
―
Hold
―
Assigned
11/04/24
Guggenheim
$15→$18
Buy
-23.40%
Downside
Reiterated
10/01/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$26
Hold
10.64%
Upside
Downgraded
06/05/25
BTIG
$25→$30
Buy
27.66%
Upside
Reiterated
05/29/25
Bank of America Securities
$25→$26.75
Buy
13.83%
Upside
Reiterated
05/13/25
Wells Fargo
$25→$27
Buy
14.89%
Upside
Reiterated
05/12/25
Morgan Stanley
$20→$25
Buy
6.38%
Upside
Reiterated
05/09/25
Leerink Partners
$26.5→$28.5
Buy
21.28%
Upside
Reiterated
05/06/25
Mizuho Securities
$22
Buy
-6.38%
Downside
Reiterated
03/12/25
Jefferies
$25
Buy
6.38%
Upside
Reiterated
03/06/25
Analysts Are Bullish on These NA Stocks: BrightSpring Health Services, Inc. (BTSG), Serve Robotics Inc (SERV)We remain bullish on BTSG and highlight how the recent sell-off in the stock has brought its valuation down to a very compelling level at 10.5x '25 EBITDA. Growth across BTSG's businesses is robust, which puts consolidated EBITDA growth around mid-teens %, and mgmt continues to execute & deliver consistent beats and raises that together, merit multiple expansion/stock upside from current levels. DC concerns are unwarranted. 4Q Results & Consistent With Pre-Release, Guidance Raised Already. BTSG's 4Q print was in-line with their pre-release from Jan, with Revs coming in at $3.05B & EBITDA at $167MM. Despite only issuing their initial FY25 guide in Jan, mgmt inched both top-line ($100MM higher from Rx segment) and EBITDA ($5MM raise vs. prior $547.5MM mid-pt) higher.
UBS
$22→$30
Buy
27.66%
Upside
Reiterated
01/29/25
Unknown AnalystGoldman Sachs
Not Ranked
Goldman Sachs
$22
Buy
-6.38%
Downside
Reiterated
12/16/24
reiterate our Buy ratings on BTSG ($22 target price, 22% upside)
CJS Securities
$27
Buy
14.89%
Upside
Initiated
12/12/24
Deutsche Bank
$13→$20
Buy
-14.89%
Downside
Reiterated
11/04/24
Unknown AnalystKeyBanc
Not Ranked
KeyBanc
―
Hold
―
Assigned
11/04/24
Guggenheim
$15→$18
Buy
-23.40%
Downside
Reiterated
10/01/24
Best Analysts Covering BrightSpring Health Services, Inc.
1 Month
xxx
Success Rate
5/7 ratings generated profit
Average Return
+5.30%
reiterated a xxx
rating 30 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +5.30% per trade.
3 Months
xxx
Success Rate
9/10 ratings generated profit
Average Return
+21.42%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 90.00% of your transactions generating a profit, with an average return of +21.42% per trade.
1 Year
Success Rate
10/10 ratings generated profit
Average Return
+67.82%
reiterated a buy rating 27 days ago
Copying Stephen Baxter's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +67.82% per trade.
2 Years
xxx
Success Rate
8/8 ratings generated profit
Average Return
+82.08%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +82.08% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BTSG Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
May 25
Strong Buy
1
1
1
2
2
Buy
12
15
10
12
14
Hold
2
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
17
11
14
16
Each month's total comprises the sum of three months' worth of ratings.
BTSG Financial Forecast
BTSG Stock Forecast FAQ
What is BTSG’s average 12-month price target, according to analysts?
Based on analyst ratings, BrightSpring Health Services, Inc.’s 12-month average price target is 26.54.
What is BTSG’s upside potential, based on the analysts’ average price target?
BrightSpring Health Services, Inc. has 12.94% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BTSG a Buy, Sell or Hold?
BrightSpring Health Services, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is BrightSpring Health Services, Inc.’s price target?
The average price target for BrightSpring Health Services, Inc. is 26.54. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $22.00. The average price target represents 12.94% Increase from the current price of $23.5.
The highest analyst price target is $30.00 ,the lowest forecast is $22.00. The average price target represents 12.94% Increase from the current price of $23.5.
What do analysts say about BrightSpring Health Services, Inc.?
BrightSpring Health Services, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of BTSG?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.